Prosetta HIV capsid assembly modulator

A small molecule protein-assembly modulator (PAM) being developed by Prosetta Biosciences (erroneously referred to as Rosetta Biosciences in some contexts) for the treatment of HIV infection. This drug candidate targets the HIV-1 capsid assembly process, a critical phase in the viral lifecycle where the viral core is formed. Unlike traditional antiretrovirals that target viral enzymes like reverse transcriptase or protease, this compound modulates the kinetics and fidelity of the multi-protein assembly of the capsid (CA) protein. This mechanism is designed to produce defective viral particles or prevent the formation of the viral core entirely, thereby blocking replication. The program utilizes Prosetta's proprietary discovery platform, which focuses on the role of host cell proteins in facilitating the assembly of viral protein complexes.

Other names

Rosetta Biosciences HIV capsid assembly programProsetta HIV programHIV capsid assembly modulatorHIV Program